Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522379 · ClinicalTrials.gov registry record · Phase 3
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
A Phase 3 study of Parkinson's Disease, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
- 20
- Study locations
NCT00522379: Completed Phase 3 study of Parkinson's Disease, sponsored by UCB Pharma.
NCT00522379 is a Phase 3 study of Parkinson's Disease that has completed, run by UCB Pharma. The registered enrollment target is 514 participants, below the 632-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00522379, a Phase 3 study of Parkinson's Disease, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
Primary Outcome
Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rotigotine
Study Locations (20)
California
- - Fountain Valley
- - Fresno
- - Irvine
- - La Jolla
- - Loma Linda
- - Oxnard
Florida
- - Boca Raton
- - Bradenton
- - Jacksonville
- - Miami
- - Naples
Arizona
- - Gilbert
- - Peoria
- - Phoenix
- - Scottsdale
Alabama
- - Birmingham
- - Tuscaloosa
Arkansas
- - Little Rock
Colorado
- - Aurora
Connecticut
- - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00522379 record still lists
NCT00522379 is an interventional study that assigns participants to a tested intervention. The registered 514 participants enrollment target is mid-sized for trials with a published cap, below the 632-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00522379 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00522379 about?
NCT00522379 is a clinical study titled "Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch". The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
What is the current status of trial NCT00522379?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2007-07. Estimated completion is 2011-07.
What conditions does trial NCT00522379 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00522379?
The interventions under investigation include: Placebo (OTHER), Rotigotine (DRUG).
Who is sponsoring clinical trial NCT00522379?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00522379 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00522379's enrollment target sits among peer trials
514 16th of 158 higher than 143 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
Deep Brain Stimulation for Parkinson's Disease Trial
COMPLETED · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- NCT06716606 · 514 participants · Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- NCT05577819 · 515 participants · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia